Top

Published in:

Open Access 01-09-2017 | Oncology

Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI

Authors: Auni Lindgren, Maarit Anttila, Suvi Rautiainen, Otso Arponen, Annukka Kivelä, Petri Mäkinen, Kirsi Härmä, Kirsi Hämäläinen, Veli-Matti Kosma, Seppo Ylä-Herttuala, Ritva Vanninen, Hanna Sallinen

Published in: European Radiology | Issue 9/2017

Abstract

Objectives

We aimed to investigate whether apparent diffusion coefficients (ADCs) measured by 3.0T diffusion-weighted magnetic resonance imaging (DWI) associate with histological aggressiveness of ovarian cancer (OC) or predict the clinical outcome. This prospective study enrolled 40 patients with primary OC, treated 2011-2014.

Methods

DWI was performed prior to surgery. Two observers used whole lesion single plane region of interest (WLsp-ROI) and five small ROIs (S-ROI) to analyze ADCs. Samples from tumours and metastases were collected during surgery. Immunohistochemistry and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to measure the expression of vascular endothelial growth factor (VEGF) and its receptors.

Results

The interobserver reliability of ADC measurements was excellent for primary tumours ICC 0.912 (WLsp-ROI). Low ADCs significantly associated with poorly differentiated OC (WLsp-ROI P = 0.035). In primary tumours, lower ADCs significantly associated with high Ki-67 (P = 0.001) and low VEGF (P = 0.001) expression. In metastases, lower ADCs (WLsp-ROI) significantly correlated with low VEGF receptors mRNA levels. ADCs had predictive value; 3-year overall survival was poorer in patients with lower ADCs (WLsp-ROI P = 0.023, S-ROI P = 0.038).

Conclusion

Reduced ADCs are associated with histological severity and worse outcome in OC. ADCs measured with WLsp-ROI may serve as a prognostic biomarker of OC.

Key Points

• Reduced ADCs correlate with prognostic markers: poor differentiation and high Ki-67 expression

• ADCs also significantly correlated with VEGF protein expression in primary tumours

• Lower ADC values are associated with poorer survival in ovarian cancer

• Whole lesion single plane-ROI ADCs may be used as a prognostic biomarker in OC

Ledermann JA, Raja FA, Fotopoulou C et al (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi24–vi32CrossRefPubMed

du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 115:1234–1244CrossRefPubMed

Vergote I, Tropé CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953CrossRefPubMed

Khouja MH, Baekelandt M, Nesland JM, Holm R (2007) The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 26:418–425CrossRefPubMed

Claesson-Welsh L, Welsh M (2013) VEGFA and tumour angiogenesis. J Intern Med 273:114–127CrossRefPubMed

Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469–478PubMed

Joukov V, Pajusola K, Kaipainen A et al (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:1751PubMedPubMedCentral

Achen MG, Jeltsch M, Kukk E et al (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 95:548–553CrossRefPubMedPubMedCentral

Thomassin-Naggara I, Toussaint I, Perrot N et al (2011) Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. Radiology 258:793–803CrossRefPubMed

10.

Fujii S, Matsusue E, Kanasaki Y et al (2008) Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol 18:18–23CrossRefPubMed

11.

Oh J-W, Rha SE, Oh SN et al (2015) Diffusion-weighted MRI of epithelial ovarian cancers: correlation of apparent diffusion coefficient values with histologic grade and surgical stage. Eur J Radiol 84:590–595CrossRefPubMed

12.

Sala E, Kataoka MY, Priest AN et al (2012) Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology 263:149–159CrossRefPubMed

13.

Vargas HA, Barrett T, Sala E (2013) MRI of ovarian masses. J Magn Reson Imaging 37:265–281CrossRefPubMed

14.

Kyriazi S, Collins DJ, Morgan VA et al (2010) Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer. Radiographics 30:1269–1285CrossRefPubMed

15.

Chenevert TL, Brunberg JA, Pipe JG (1990) Anisotropic diffusion in human white matter: demonstration with MR techniques in vivo. Radiology 177:401–405CrossRefPubMed

16.

Fan X, Zhang H, Meng S et al (2015) Role of diffusion-weighted magnetic resonance imaging in differentiating malignancies from benign ovarian tumors. Int J Clin Exp Med 8:19928–19937PubMedPubMedCentral

17.

Arponen O, Arponent O, Sudah M et al (2015) Diffusion-weighted imaging in 3.0 tesla breast MRI: diagnostic performance and tumor characterization using small subregions vs. whole tumor regions of interest. PLoS One 10:e0138702CrossRefPubMed

18.

Bae H, Yoshida S, Matsuoka Y et al (2014) Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. Int Urol Nephrol 46:555–561CrossRefPubMed

19.

Rautiainen S, Könönen M, Sironen R et al (2015) Preoperative axillary staging with 3.0-T breast MRI: clinical value of diffusion imaging and apparent diffusion coefficient. PLoS One 10:e0122516CrossRefPubMedPubMedCentral

20.

Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483CrossRefPubMed

21.

Sallinen H, Anttila M, Narvainen J et al (2009) Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther 17:278–284CrossRefPubMed

22.

Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA (2003) Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS 111:1011–1018CrossRefPubMed

23.

Harry VN, Semple SI, Parkin DE, Gilbert FJ (2010) Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 11:92–102CrossRefPubMed

24.

Tuppurainen L, Sallinen H, Hakkarainen H et al (2013) Functional MRI measurements to predict early adenoviral gene therapy response in ovarian cancer mouse model. J Genet Syndr Gene Ther. doi:10.4172/2157-7412.1000171

25.

Friedlander ML (1998) Prognostic factors in ovarian cancer. Semin Oncol 25:305–314PubMed

26.

Mori N, Ota H, Mugikura S et al (2015) Luminal-type breast cancer: correlation of apparent diffusion coefficients with the Ki-67 labeling index. Radiology 274:66–73CrossRefPubMed

27.

Moteki T, Ishizaka H (2000) Diffusion-weighted EPI of cystic ovarian lesions: evaluation of cystic contents using apparent diffusion coefficients. J Magn Reson Imaging 12:1014–1019CrossRefPubMed

28.

Katayama M, Masui T, Kobayashi S et al (2002) Diffusion-weighted echo planar imaging of ovarian tumors: is it useful to measure apparent diffusion coefficients? J Comput Assist Tomogr 26:250–256CrossRefPubMed

29.

Miccò M, Vargas HA, Burger IA et al (2014) Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. Eur J Radiol 83:1169–1176CrossRefPubMed

30.

Martins SF, Reis RM, Rodrigues AM et al (2011) Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol 2:272–280PubMedPubMedCentral

31.

Paley PJ, Staskus KA, Gebhard K et al (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98–106CrossRefPubMed

32.

Martins SF, Garcia EA, Luz MAM et al (2013) Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics 10:55–67PubMed

33.

Gadducci A, Viacava P, Cosio S et al (2003) Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res 23:3001–3008PubMed

34.

Yokoyama Y, Charnock-Jones DS, Licence D et al (2003) Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 88:237–244CrossRefPubMedPubMedCentral

35.

Zhou Y, Liu J, Liu C et al (2016) Intravoxel incoherent motion diffusion weighted MRI of cervical cancer - correlated with tumor differentiation and perfusion. Magn Reson Imaging 34:1050–1056CrossRefPubMed

36.

Cho GY, Moy L, Kim SG et al (2015) Evaluation of breast cancer using intravoxel incoherent motion (IVIM) histogram analysis: comparison with malignant status, histological subtype, and molecular prognostic factors. Eur Radiol. doi:10.1007/s00330-015-4087-3 PubMedCentral

Title: Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI
Authors: Auni Lindgren
Maarit Anttila
Suvi Rautiainen
Otso Arponen
Annukka Kivelä
Petri Mäkinen
Kirsi Härmä
Kirsi Hämäläinen
Veli-Matti Kosma
Seppo Ylä-Herttuala
Ritva Vanninen
Hanna Sallinen
Publication date: 01-09-2017
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 9/2017
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-017-4786-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 9/2017

A simple classification system (the Tree flowchart) for breast MRI can reduce the number of unnecessary biopsies in MRI-only lesions

Chemical shift effect predicting lymph node status in rectal cancer using high-resolution MR imaging with node-for-node matched histopathological validation

Comparison between automated breast volume scanner (ABVS) versus hand-held ultrasound as a second look procedure after magnetic resonance imaging

Non-contrast magnetic resonance imaging for bladder cancer: fused high b value diffusion-weighted imaging and T2-weighted imaging helps evaluate depth of invasion

Clinical implications of nonspecific pulmonary nodules identified during the initial evaluation of patients with head and neck squamous cell carcinoma

Shear wave elastography in the diagnosis of breast non-mass lesions: factors associated with false negative and false positive results